BioPharma dealmaking is still going strong this summer. We're highlighting a few companies that caught our EyesOn team attention. Check out details on the Roche + Hanmi, Leo Pharma + Tanabe, and the SK BioPharma + Biohaven deals. By paying $190 million up front for a clinical-stage UCN2 (urocortin-2) analogue from South Korea’s Hanmi Pharm, Roche has advanced its obesity approach into unprecedented territory. Eli Lilly investigated the mechanism in a heart failure medicatio

This week we're sharing a couple of articles focused on competitive advantage in US BioPharma. Take a look at how the Oral GLP-1 market is shaping up, and the new US Initiative Operation TrialBlazer is trying to boost US Early-Stage Clinical Development Capabilities.